hTERT antisense oligodeoxynucleotide enhances the sensitivity of acute lymphoblastic leukemia cells from relapse patients to cisplatin
- VernacularTitle:hTERT基因反义核酸提高原代复发急性淋巴细胞白血病细胞对顺铂敏感性的研究
- Author:
Wenyu LI
;
Yuan ZHANG
- Publication Type:Journal Article
- Keywords:
Genes,hTERT;
Oligonucleotides,antisense;
Telomerase;
Leukemia;
Apoptosis;
Cisplatin
- From:
Chinese Journal of Pathophysiology
2006;22(11):2223-2226
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore whether human telomerase reverse transcriptase (hTERT) antisense oligodeoxynucleotide (ASODN) could enhance the sensitivity of acute lymphoblastic leukemia cells from relapse patients to cisplatin. METHODS: The expression levels of hTERT protein were detected by immunofluorescence using fluorescence isothiocyanate (FITC), the number of viable cells was determined using the trypan blue dye exclusion assay, and apoptosis was detected by morphological observation and flow cytometric cell cycle analysis. RESULTS: The expression of hTERT protein was inhibited after treatment with hTERT ASODN. Treatment with cisplatin combined with hTERT ASODN had significantly reduced the number of viable acute lymphoblastic leukemic (ALL) cells (P<0.05). In morphological observation of apoptotic cells using Hoechst33258 and PI double staining techniques, cells displayed classic apoptotic changes in the presence of cisplatin or cisplatin combined with hTERT ASODN or ASODN at 48 h. Apoptotic rates of cells treated with cisplatin and ASODN were higher than that of cells treated with cisplatin alone (P<0.05). CONCLUSION: hTERT ASODN could increase sensitivity of cultured primary acute lymphoblastic leukemia cells from relapse patients to cisplatin.
